PrepSolution

Nursing · Study journal

FNP Pharmacology Practice Questions: Boxed Warnings and Label Rules

Eleven original FNP pharmacology questions on contraindications, boxed warnings and administration rules for common primary-care drugs, each keyed to the FDA label.

By Elena R.Published Reviewed by PrepSolution Editorial Team9 min read
Inside this articleNursing
Section preview 01

Contraindications

A 66-year-old with type 2 diabetes has an eGFR of 26 mL/min/1.73 m2. What does the metformin label say?

Read this section
On this page

Pharmacology on the FNP boards is about safe prescribing in primary care. The questions rarely ask for a dose. They ask who should not get a drug, what a boxed warning says, and how to tell a patient to take it. The 11 questions below are keyed to the FDA label for each drug.

They are written for candidates using FNP-C exam prep, which follows the NPCB (formerly AANPCB) FNP blueprint; therapeutics, including pharmacologic therapy, is one of the knowledge areas NPCB lists. See the AANP FNP exam blueprint guide for the full list.

This set is exam practice written from the USPSTF, CDC, AAP and FDA label sources listed under References. The questions are original PrepSolution items, not NPCB or ANCC exam questions. It is not clinical guidance for any patient, and it has not been reviewed by a credentialed nurse practitioner.

Contraindications

Question 1: Metformin and kidney function

A 66-year-old with type 2 diabetes has an eGFR of 26 mL/min/1.73 m2. What does the metformin label say?

  • A. Continue at full dose
  • B. Do not use metformin when eGFR is below 30
  • C. Halve the dose
  • D. Metformin is preferred in kidney disease

Best answer: B. The label says not to use metformin in patients with eGFR below 30 mL/min/1.73 m2, that starting it is not recommended at eGFR 30 to 45, and to reassess risk and benefit if eGFR falls below 45.

  • A is not the best answer. Full-dose use is not allowed below 30.
  • C is not the best answer. Dose reduction is not the label's instruction below 30; use is ruled out.
  • D is not the best answer. The label restricts metformin in reduced kidney function.

Question 2: Sildenafil and nitrates

A 63-year-old with stable angina who uses sublingual nitroglycerin as needed asks for sildenafil. What does the label say?

  • A. Contraindicated with organic nitrates in any form
  • B. Safe if doses are separated by 4 hours
  • C. Safe at the lowest dose
  • D. Contraindicated only with long-acting nitrates

Best answer: A. The sildenafil label says it potentiates the hypotensive effects of nitrates, and use in patients who use nitric oxide donors such as organic nitrates or nitrites in any form is contraindicated.

  • B is not the best answer. The label does not allow use with separation.
  • C is not the best answer. Dose does not change the contraindication.
  • D is not the best answer. The label says "in any form," which includes as-needed sublingual nitroglycerin.

Question 3: Codeine in children

A parent asks for codeine for pain after their 9-year-old's tonsillectomy. What does the codeine label say?

  • A. Codeine is fine at a weight-based dose
  • B. Codeine is allowed if the child is not an ultra-rapid metabolizer
  • C. Codeine is preferred over other opioids for children
  • D. Codeine is contraindicated in children younger than 12, and in those under 18 after tonsillectomy or adenoidectomy

Best answer: D. The label contraindicates codeine in children younger than 12 and in children younger than 18 following tonsillectomy and/or adenoidectomy, after reports of respiratory depression and death, many in ultra-rapid CYP2D6 metabolizers.

  • A is not the best answer. The contraindication applies regardless of dosing.
  • B is not the best answer. Metabolizer status is not tested before the contraindication applies; the child is under 12.
  • C is not the best answer. The label restricts codeine in children.

Question 4: A fluoroquinolone and myasthenia gravis

A 45-year-old with myasthenia gravis has an uncomplicated urinary infection. Ciprofloxacin is being considered. What does the label say?

  • A. Safe with dose reduction
  • B. Preferred because it does not affect muscle
  • C. Avoid ciprofloxacin in patients with known myasthenia gravis
  • D. Safe if pyridostigmine is held

Best answer: C. The label warns that fluoroquinolones, including ciprofloxacin, may exacerbate muscle weakness in patients with myasthenia gravis and says to avoid ciprofloxacin in patients with a known history of myasthenia gravis.

  • A is not the best answer. The label says avoid, not reduce the dose.
  • B is not the best answer. The label warns of worsening muscle weakness.
  • D is not the best answer. Holding the myasthenia treatment is not what the label directs.

Question 5: Isotretinoin and pregnancy

A 19-year-old with severe nodular acne may start isotretinoin. How does the label control access?

  • A. Any prescriber may write it with no program
  • B. Through a restricted REMS program called iPLEDGE because of embryo-fetal toxicity
  • C. Only after age 25
  • D. Only with a dermatologist's co-signature

Best answer: B. The label says isotretinoin is available only through a restricted Risk Evaluation and Mitigation Strategy program called iPLEDGE because of the risk of embryo-fetal toxicity, and it carries a boxed warning that it is contraindicated in pregnancy.

  • A is not the best answer. Access is restricted through the REMS program.
  • C is not the best answer. There is no age 25 rule in the label.
  • D is not the best answer. The control is the iPLEDGE REMS, not a co-signature.

Boxed warnings

Question 6: An SSRI for a young adult

A 20-year-old is starting sertraline for depression. What does the boxed warning require?

  • A. Close monitoring for clinical worsening and emergence of suicidal thoughts and behaviors
  • B. No special monitoring
  • C. A baseline ECG
  • D. Weekly blood levels

Best answer: A. The boxed warning says antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies, and that all antidepressant-treated patients should be closely monitored. The patient guide names people 24 and younger, especially in the first months or after dose changes.

  • B is not the best answer. The boxed warning calls for close monitoring.
  • C is not the best answer. An ECG is not the boxed warning's requirement.
  • D is not the best answer. Sertraline does not require blood level monitoring under the boxed warning.

Question 7: Montelukast for allergic rhinitis

A 16-year-old with mild seasonal allergic rhinitis controlled on a nasal steroid asks to switch to montelukast. What does the montelukast label advise?

  • A. Montelukast is first-line for all allergic rhinitis
  • B. It may be used without discussing risks
  • C. Because of serious neuropsychiatric events, reserve it for allergic rhinitis with inadequate response or intolerance to other therapies
  • D. It is contraindicated under 18

Best answer: C. The boxed warning describes serious neuropsychiatric events with montelukast and says to reserve it for patients with allergic rhinitis who have an inadequate response or intolerance to alternative therapies.

  • A is not the best answer. The label restricts montelukast in allergic rhinitis.
  • B is not the best answer. The boxed warning calls for weighing these risks.
  • D is not the best answer. There is no under-18 contraindication.

Question 8: Thyroid hormone for weight loss

A euthyroid 35-year-old asks for levothyroxine to help with weight loss. What does the boxed warning say?

  • A. It is effective at low doses
  • B. It may be used if TSH is normal
  • C. It is safe with diet changes
  • D. Thyroid hormones should not be used for the treatment of obesity or for weight loss

Best answer: D. The boxed warning says thyroid hormones, including levothyroxine, alone or with other agents, should not be used for the treatment of obesity or for weight loss.

  • A is not the best answer. The label does not support weight-loss use at any dose.
  • B is not the best answer. A normal TSH is the reason not to give it, not a reason to give it.
  • C is not the best answer. Diet changes do not alter the boxed warning.

Question 9: Lithium monitoring

Why does the lithium label carry a boxed warning about toxicity?

  • A. Toxicity occurs only with overdose
  • B. Lithium toxicity is closely related to serum concentrations and can occur at doses close to therapeutic levels, so serum levels must be available
  • C. Lithium is not monitored
  • D. Toxicity is only a concern in children

Best answer: B. The boxed warning says lithium toxicity is closely related to serum lithium concentrations and can occur at doses close to therapeutic concentrations, and that facilities for prompt and accurate serum lithium determinations should be available before starting.

  • A is not the best answer. Toxicity can occur near therapeutic doses, not only in overdose.
  • C is not the best answer. The warning requires access to serum level testing.
  • D is not the best answer. The warning is not limited to children.

How to take it

Question 10: Teaching alendronate

Which instruction comes from the alendronate label?

  • A. Take with breakfast and orange juice
  • B. Take at bedtime with milk
  • C. Chew the tablet
  • D. Swallow with 6 to 8 ounces of plain water at least 30 minutes before the first food, drink or medication, and do not lie down for at least 30 minutes

Best answer: D. The label tells patients to swallow the tablet whole with 6 to 8 ounces of plain water at least 30 minutes before the first food, drink or medication of the day, and not to lie down for at least 30 minutes and until after food. Inability to sit or stand upright for 30 minutes is a contraindication.

  • A is not the best answer. Food and juice before the dose are what the label tells patients to avoid.
  • B is not the best answer. Lying down after the dose is what the label forbids.
  • C is not the best answer. The label says to swallow it whole.

Question 11: Teaching levothyroxine

A patient starting levothyroxine for hypothyroidism also takes a calcium supplement. Which instruction matches the Levoxyl label?

  • A. Take with breakfast and the calcium
  • B. Take at bedtime with a snack
  • C. Take once daily on an empty stomach, 30 to 60 minutes before breakfast, at least 4 hours apart from drugs that interfere with absorption
  • D. Take twice daily with meals

Best answer: C. The label says to take levothyroxine once daily on an empty stomach, one-half to one hour before breakfast with a full glass of water, and at least 4 hours before or after drugs known to interfere with absorption.

  • A is not the best answer. Taking it with food and calcium is what the label separates.
  • B is not the best answer. The label says empty stomach before breakfast.
  • D is not the best answer. The label gives once-daily dosing.

Label rules in this set

DrugRule
MetforminDo not use if eGFR below 30; do not start at 30 to 45
SildenafilContraindicated with organic nitrates in any form
CodeineContraindicated under 12, and under 18 after tonsillectomy or adenoidectomy
CiprofloxacinAvoid in myasthenia gravis; tendinitis and tendon rupture warnings
IsotretinoiniPLEDGE REMS; contraindicated in pregnancy
SertralineBoxed warning: suicidal thoughts in pediatric and young adult patients
MontelukastBoxed warning: neuropsychiatric events; reserve for allergic rhinitis after other options
LevothyroxineNot for obesity or weight loss; empty stomach, 4 hours from interfering drugs
LithiumToxicity near therapeutic levels; serum levels needed
AlendronatePlain water, 30 minutes before food, stay upright 30 minutes
One rule per drug, from its FDA label.

How should you use this set?

For each drug, learn the one rule that would stop you prescribing it or change how the patient takes it. That is what the boards test. For practice across the blueprint, see FNP-C exam prep, and for the cardiovascular drug rules, the FNP cardiovascular practice questions.

Elena R.

PrepSolution Content Editor, Nurse Practitioner Certification

About PrepSolution

References

  1. [1] FDA label (2026). Metformin hydrochloride tablets. FDA label. FDA label
  2. [2] FDA label (2026). Sertraline hydrochloride tablets. FDA label. FDA label
  3. [3] FDA label (2026). Viagra (sildenafil citrate). FDA label. FDA label
  4. [4] FDA label (2026). Levoxyl (levothyroxine sodium). FDA label. FDA label
  5. [5] FDA label (2026). Alendronate sodium tablets. FDA label. FDA label
  6. [6] FDA label (2026). Montelukast sodium tablets. FDA label. FDA label
  7. [7] FDA label (2026). Codeine sulfate tablets. FDA label. FDA label
  8. [8] FDA label (2026). Ciprofloxacin tablets. FDA label. FDA label
  9. [9] FDA label (2026). Lithium carbonate capsules. FDA label. FDA label
  10. [10] FDA label (2026). Isotretinoin capsules. FDA label. FDA label

Help us improve this guide

How helpful was this article?

One tap helps us understand what’s useful.

Not helpful → Very helpful

Frequently asked questions

Mostly not. Pharmacology items tend to test indications, contraindications, boxed warnings, monitoring and patient teaching. This set keys only rules stated in the FDA label.

The label says not to use it when eGFR is below 30 mL/min/1.73 m2, and not to start it at 30 to 45.

The label contraindicates codeine in children under 12 and in those under 18 after tonsillectomy or adenoidectomy.

With 6 to 8 ounces of plain water at least 30 minutes before the first food, drink or medication of the day, staying upright for at least 30 minutes.

It warns of serious neuropsychiatric events and advises reserving montelukast for allergic rhinitis that has not responded to or tolerated other therapies.

No. They are original PrepSolution practice items written from the FDA labels listed under References. They have not been reviewed by a credentialed nurse practitioner and are not clinical guidance.

Keep practicing for the FNP-C.

Review the study tools, access options and price, or start with free practice.

Related Articles